4.5200
+0.1300
+(2.96%)
At close: January 13 at 4:00:01 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 2 | 6 | 4 |
| Avg. Estimate | -0.02 | -0.17 | -0.69 | -0.64 |
| Low Estimate | -0.06 | -0.19 | -0.79 | -0.76 |
| High Estimate | 0.05 | -0.14 | -0.57 | -0.51 |
| Year Ago EPS | -0.1 | -0.16 | -0.92 | -0.69 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 5 | 8 | 7 |
| Avg. Estimate | 27.41M | 13.98M | 65.29M | 66.61M |
| Low Estimate | 20.5M | 11.29M | 58.38M | 63M |
| High Estimate | 33.43M | 16.5M | 71.31M | 76.6M |
| Year Ago Sales | 26.56M | 17.07M | 70.14M | 65.29M |
| Sales Growth (year/est) | 3.20% | -18.09% | -6.92% | 2.02% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.14 | -0.14 | -0.24 | -0.21 |
| EPS Actual | -0.1 | -0.16 | -0.32 | -0.29 |
| Difference | 0.04 | -0.02 | -0.08 | -0.08 |
| Surprise % | 26.07% | -17.07% | -34.68% | -35.51% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.02 | -0.17 | -0.69 | -0.64 |
| 7 Days Ago | -0.02 | -0.17 | -0.69 | -0.64 |
| 30 Days Ago | -0.02 | -0.17 | -0.69 | -0.64 |
| 60 Days Ago | -0.02 | -0.17 | -0.69 | -0.64 |
| 90 Days Ago | -0.02 | -0.19 | -0.65 | -0.65 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | 1 | 2 |
| Up Last 30 Days | 2 | -- | 1 | 3 |
| Down Last 7 Days | 2 | 2 | 4 | -- |
| Down Last 30 Days | 2 | 2 | 4 | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| CDXS | 79.06% | -3.13% | 25.35% | 7.25% |
| S&P 500 | 8.58% | 11.41% | 13.97% | 13.43% |
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 11/22/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 11/15/2024 |
| Reiterates | Benchmark: Hold | 11/4/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/20/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 8/29/2024 |
| Downgrade | Benchmark: Buy to Hold | 8/19/2024 |
Related Tickers
ALDX Aldeyra Therapeutics, Inc.
4.7700
-3.44%
CCCC C4 Therapeutics, Inc.
3.5000
-4.50%
IMUX Immunic, Inc.
1.0700
+1.90%
GBIO Generation Bio Co.
0.9200
-0.59%
INZY Inozyme Pharma, Inc.
1.7200
-13.78%
CHRS Coherus BioSciences, Inc.
1.4700
0.00%
PRQR ProQR Therapeutics N.V.
2.2700
-6.20%
ACLX Arcellx, Inc.
67.36
-2.49%
IPSC Century Therapeutics, Inc.
0.9701
-2.01%
ADCT ADC Therapeutics SA
1.7200
-8.51%